{"id":26225,"date":"2024-07-12T14:34:48","date_gmt":"2024-07-12T21:34:48","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=26225"},"modified":"2025-07-16T17:22:31","modified_gmt":"2025-07-17T00:22:31","slug":"a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/","title":{"rendered":"Una descripci\u00f3n general completa de Novoeight: tratamiento de la hemofilia A con tecnolog\u00eda recombinante"},"content":{"rendered":"<p>El Novoeight (Turoctocog alfa) es un factor VIII antihemof\u00edlico producido mediante tecnolog\u00eda recombinante. Este medicamento se prescribe generalmente para tratar o prevenir episodios hemorr\u00e1gicos en pacientes con&nbsp;<a href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/hemophilia-a-vs-b-whats-the-difference\/\">hemofilia A<\/a>.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-84318ddbb057611ba11c711a1142894b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHable con un especialista sobre la asistencia con los copagos\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>Los pacientes con hemofilia A carecen del factor de coagulaci\u00f3n VIII (una prote\u00edna de coagulaci\u00f3n sangu\u00ednea), y Novoeight reemplaza el factor de coagulaci\u00f3n VIII faltante, ayudando as\u00ed a la sangre a coagularse.&nbsp;<\/p>\n\n\n\n<p>El Novoeight fue aprobado por primera vez por la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA) en febrero de 2013 debido a sus resultados efectivos en uno de los m\u00e1s grandes&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23647704\/\">ensayos cl\u00ednicos<\/a>&nbsp;hasta la fecha.<\/p>\n\n\n\n<p>Este medicamento s\u00f3lo puede obtenerse mediante receta m\u00e9dica y se autoadministra despu\u00e9s de recibir capacitaci\u00f3n de un profesional de la salud.&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#What_Is_Novoeight_Used_To_Treat\" >\u00bfPara qu\u00e9 se utiliza el Novoeight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#How_Does_Novoeight_Work\" >\u00bfC\u00f3mo funciona Novoeight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#What_Are_the_Available_Dosage_Forms_and_Strengths\" >\u00bfCu\u00e1les son las formas farmac\u00e9uticas y concentraciones disponibles?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#What_Is_the_Usual_Dose_for_Patients_With_Hemophilia_A\" >\u00bfCu\u00e1l es la dosis habitual para pacientes con hemofilia A?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#Dosing_Information\" >Informaci\u00f3n de dosificaci\u00f3n<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#How_Is_Novoeight_Given\" >\u00bfC\u00f3mo se administra Novoeight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#What_Are_the_Common_Side_Effects_of_Novoeight\" >\u00bfCu\u00e1les son los efectos secundarios comunes de Novoeight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#What_Precautions_Should_You_Take_While_Taking_Novoeight\" >\u00bfQu\u00e9 precauciones debe tomar al tomar Novoeight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#Does_Novoeight_Remain_Stable_at_High_Temperatures\" >\u00bfEl Novoeight permanece estable a altas temperaturas?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#Cost\" >Costo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-what-is-novoeight-used-to-treat\"><span class=\"ez-toc-section\" id=\"What_Is_Novoeight_Used_To_Treat\"><\/span>\u00bfPara qu\u00e9 se utiliza el Novoeight?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El Novoeight se utiliza para tratar la hemofilia A en ni\u00f1os y adultos. Se utiliza para:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Controlar los episodios de sangrado en pacientes con hemofilia A<\/li>\n\n\n\n<li>Reducir la frecuencia (n\u00famero) de episodios de sangrado en pacientes con hemofilia A<\/li>\n\n\n\n<li>Prevenir sangrado durante cirug\u00edas menores o mayores en pacientes con hemofilia A&nbsp;<\/li>\n<\/ul>\n\n\n\n<p>Novoeight no se puede utilizar para el tratamiento de&nbsp;<a href=\"https:\/\/www.mayoclinic.org\/diseases-conditions\/von-willebrand-disease\/symptoms-causes\/syc-20354978\">enfermedad de von Willebrand<\/a>&nbsp;en pacientes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-does-novoeight-work\"><span class=\"ez-toc-section\" id=\"How_Does_Novoeight_Work\"><\/span>\u00bfC\u00f3mo funciona Novoeight?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>En los pacientes con hemofilia A, el factor de coagulaci\u00f3n VIII falta o no funciona correctamente, lo que provoca sangrado en las articulaciones, los m\u00fasculos o los \u00f3rganos internos.&nbsp;<\/p>\n\n\n\n<p>Novoeight contiene una sustancia activa, \u201cTuroctocog alfa\u201d, que imita la funci\u00f3n del factor de coagulaci\u00f3n VIII natural y ayuda a la sangre a formar un co\u00e1gulo.&nbsp;<\/p>\n\n\n\n<p>El Novoeight recombinante corrige la deficiencia del factor VIII reemplazando el factor de coagulaci\u00f3n VIII faltante, controlando as\u00ed temporalmente el trastorno hemorr\u00e1gico.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-are-the-available-dosage-forms-and-strengths\"><span class=\"ez-toc-section\" id=\"What_Are_the_Available_Dosage_Forms_and_Strengths\"><\/span>\u00bfCu\u00e1les son las formas farmac\u00e9uticas y concentraciones disponibles?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novoeight est\u00e1 disponible en forma de polvo liofilizado en un vial de dosis \u00fanica con las siguientes concentraciones (concentraciones): 250, 500, 1000, 1500, 2000 y 3000 UI por vial.&nbsp;<\/p>\n\n\n\n<p>El polvo se reconstituye con 4 ml de&nbsp;<a href=\"https:\/\/www.webmd.com\/drugs\/2\/drug-145556\/sodium-chloride-0-9-intravenous\/details\">0.9% cloruro de sodio<\/a>&nbsp;Soluci\u00f3n. Cada ml de soluci\u00f3n reconstituida contiene:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>250 UI (62,5 UI\/ml)<\/li>\n\n\n\n<li>500 UI (125 UI\/ml)&nbsp;<\/li>\n\n\n\n<li>1.000 UI (250 UI\/ml)<\/li>\n\n\n\n<li>1.500 UI (375 UI\/ml)<\/li>\n\n\n\n<li>2.000 UI (500 UI\/ml)<\/li>\n\n\n\n<li>3.000 UI (750 UI\/ml)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-the-usual-dose-for-patients-with-hemophilia-a\"><span class=\"ez-toc-section\" id=\"What_Is_the_Usual_Dose_for_Patients_With_Hemophilia_A\"><\/span>\u00bfCu\u00e1l es la dosis habitual para pacientes con hemofilia A?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dosing-information\"><span class=\"ez-toc-section\" id=\"Dosing_Information\"><\/span>Informaci\u00f3n de dosificaci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La dosis de Novoeight se ajusta seg\u00fan el peso corporal del paciente, la frecuencia de los episodios de sangrado, la gravedad de la deficiencia del factor VIII y el tipo de sangrado que est\u00e9 experimentando.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-for-minor-to-moderate-bleeding-or-minor-surgery\">Para sangrado leve a moderado o cirug\u00eda menor<\/h4>\n\n\n\n<p>Mantener una actividad plasm\u00e1tica del factor VIII de 20% a 40% (UI) en casos de hemorragia leve, como hemorragia muscular u oral leve, y de 30% a 60% (UI) en casos de hemorragia moderada, como hemorragia en la cavidad oral o traumatismo craneoencef\u00e1lico leve. Se administran unidades adicionales de Novoeight cada 12 a 24 horas hasta que se resuelva la hemorragia.<\/p>\n\n\n\n<p>En caso de cirug\u00eda menor, como la extracci\u00f3n de un diente, se administra de 30% a 60% de nivel normal de actividad del factor VIII cada 24 horas durante al menos 1 d\u00eda hasta lograr la curaci\u00f3n.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-for-major-bleeding-or-surgical-procedures\">Para sangrado importante o procedimientos quir\u00fargicos:<\/h4>\n\n\n\n<p>Si un paciente presenta un sangrado importante, mantenga un nivel de actividad del factor VIII plasm\u00e1tico de 60% \u2013 80% de UI normales, seguido de una dosis repetida administrada cada 8 a 24 horas hasta que el sangrado se haya resuelto.<\/p>\n\n\n\n<p>En cirug\u00edas mayores como reemplazo de articulaciones, traumatismos o&nbsp;<a href=\"https:\/\/my.clevelandclinic.org\/health\/treatments\/15605-tonsillectomy\">amigdalectom\u00eda<\/a>Se administran 60% \u2013 80% del nivel normal de actividad del factor VIII cada 8 a 24 horas hasta que se logre una cicatrizaci\u00f3n adecuada de la herida.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-dosing-for-routine-prophylaxis\">Dosificaci\u00f3n para profilaxis de rutina<\/h4>\n\n\n\n<p>Las siguientes son las dosis recomendadas de Novoeight para reducir la cantidad (frecuencia) de episodios de sangrado en ni\u00f1os y pacientes adultos con hemofilia A:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Para adultos: 20 \u2013 50 UI\/kg de Novoeight tres veces por semana o 20 \u2013 40 UI\/kg de Novoeight d\u00eda por medio.<\/li>\n\n\n\n<li>Para ni\u00f1os (menores de 12 a\u00f1os): 25 \u2013 60 UI\/kg de Novoeight tres veces por semana o 25 \u2013 50 UI\/kg de Novoeight d\u00eda por medio.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-is-novoeight-given\"><span class=\"ez-toc-section\" id=\"How_Is_Novoeight_Given\"><\/span>\u00bfC\u00f3mo se administra Novoeight?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novoeight se administra como infusi\u00f3n intravenosa (a trav\u00e9s de una vena) (lentamente durante 2 a 5 minutos) directamente en el torrente sangu\u00edneo.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-83f4a0233b00ab15eef9646d62e33be9\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia financiera\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-are-the-common-side-effects-of-novoeight\"><span class=\"ez-toc-section\" id=\"What_Are_the_Common_Side_Effects_of_Novoeight\"><\/span>\u00bfCu\u00e1les son los efectos secundarios comunes de Novoeight?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Adem\u00e1s de sus prometedores resultados en pacientes con hemofilia A, el Novoeight puede causar algunos efectos adversos. Los efectos secundarios m\u00e1s comunes observados durante los ensayos cl\u00ednicos (\u2265 1% de pacientes) son:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reacci\u00f3n en el lugar de la inyecci\u00f3n, como hinchaz\u00f3n, picaz\u00f3n, dolor o enrojecimiento.&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/radiopaedia.org\/articles\/pyrexia?lang=us\">Pirexia<\/a>&nbsp;(fiebre alta)<\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects.jpg\" alt=\"Patient experiencing potential side effects of Novoeight treatment.\" class=\"wp-image-26273\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-side-effects-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>Novoeight rara vez causa reacciones de hipersensibilidad (al\u00e9rgicas) y, en algunos casos, pueden progresar a reacciones graves.&nbsp;<a href=\"https:\/\/www.mayoclinic.org\/diseases-conditions\/anaphylaxis\/symptoms-causes\/syc-20351468\">anafilaxia<\/a>&nbsp;(incluido el shock anafil\u00e1ctico). Los primeros signos de una reacci\u00f3n al\u00e9rgica, que puede progresar a anafilaxia, pueden incluir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Erupciones o urticaria<\/li>\n\n\n\n<li>Dificultad para respirar o tragar<\/li>\n\n\n\n<li>Hinchaz\u00f3n de los labios y la lengua.<\/li>\n\n\n\n<li>Mareo<\/li>\n\n\n\n<li>Mareos o p\u00e9rdida del conocimiento<\/li>\n\n\n\n<li>Piel p\u00e1lida y fr\u00eda<\/li>\n\n\n\n<li>ritmo card\u00edaco acelerado&nbsp;<\/li>\n\n\n\n<li>Cara o manos enrojecidas o hinchadas&nbsp;<\/li>\n<\/ul>\n\n\n\n<p>Si experimenta estos s\u00edntomas, suspenda su uso y consulte a su proveedor de atenci\u00f3n m\u00e9dica de inmediato para buscar el tratamiento adecuado.&nbsp;<\/p>\n\n\n\n<p>Podr\u00eda producirse una reacci\u00f3n al\u00e9rgica debido a los inhibidores del factor VIII, un tipo de anticuerpo producido por el sistema inmunitario contra el factor VIII. Estos inhibidores impiden el correcto funcionamiento del Novoeight, lo que provoca la p\u00e9rdida del control del sangrado.&nbsp;<\/p>\n\n\n\n<p>Por lo tanto, los pacientes que experimentan reacciones al\u00e9rgicas deben ser evaluados para detectar la presencia de un inhibidor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-precautions-should-you-take-while-taking-novoeight\"><span class=\"ez-toc-section\" id=\"What_Precautions_Should_You_Take_While_Taking_Novoeight\"><\/span>\u00bfQu\u00e9 precauciones debe tomar al tomar Novoeight?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Consulte siempre a su profesional de la salud antes de tomar este medicamento. Informe a su m\u00e9dico si:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00bfEst\u00e1 embarazada o planea quedar embarazada?<\/li>\n\n\n\n<li>\u00bfEst\u00e1 amamantando?<\/li>\n\n\n\n<li>Es al\u00e9rgico a cualquier componente del producto recombinante Novoeight<\/li>\n\n\n\n<li>Son al\u00e9rgicos a las prote\u00ednas del h\u00e1mster.<\/li>\n\n\n\n<li>\u00bfEst\u00e1 tomando alg\u00fan medicamento, incluidos medicamentos sin receta (medicamentos a base de hierbas) y suplementos diet\u00e9ticos?<\/li>\n\n\n\n<li>Han dado positivo en la prueba de inhibidores del factor VIII&nbsp;<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-does-novoeight-remain-stable-at-high-temperatures\"><span class=\"ez-toc-section\" id=\"Does_Novoeight_Remain_Stable_at_High_Temperatures\"><\/span>\u00bfEl Novoeight permanece estable a altas temperaturas?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>S\u00ed, el Novoeight tiene la mayor estabilidad y se puede almacenar hasta 3 meses a 40 \u00b0C. Tambi\u00e9n se puede almacenar hasta 12 meses a 30 \u00b0C (temperatura ambiente).&nbsp;<\/p>\n\n\n\n<p>Despu\u00e9s de la reconstituci\u00f3n, puede conservar el medicamento durante 2 horas a 104 \u00b0F y 4 horas hasta 86 \u00b0F.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cost\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Costo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El polvo intravenoso de Novoeight (recombinante) cuesta aproximadamente $12 por un vial de polvo liofilizado inyectable. Sin embargo, el precio puede variar seg\u00fan la farmacia que visite.&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>El Novoeight (Turoctocog alfa) es un factor VIII antihemof\u00edlico producido mediante tecnolog\u00eda recombinante. Este medicamento se prescribe generalmente para tratar o prevenir episodios hemorr\u00e1gicos en pacientes con hemofilia A. Los pacientes con hemofilia A carecen del factor VIII de coagulaci\u00f3n (una prote\u00edna que coagula la sangre), y el Novoeight lo reemplaza, facilitando as\u00ed la coagulaci\u00f3n de la sangre.\u00a0<\/p>","protected":false},"author":7,"featured_media":26226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[6],"tags":[8],"class_list":["post-26225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hemophilia","tag-dr-christine-leduc"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Learn how Novoeight is used to treat Hemophilia A. Topics include how the drug works, what it treats, side effects, dosages, and more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Learn how Novoeight is used to treat Hemophilia A. Topics include how the drug works, what it treats, side effects, dosages, and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-12T21:34:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-17T00:22:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Christine Leduc, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Christine Leduc, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/\"},\"author\":{\"name\":\"Dr. Christine Leduc, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\"},\"headline\":\"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology\",\"datePublished\":\"2024-07-12T21:34:48+00:00\",\"dateModified\":\"2025-07-17T00:22:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/\"},\"wordCount\":960,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/novoeight.jpg\",\"keywords\":[\"Dr. Christine Leduc\"],\"articleSection\":[\"Hemophilia\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/\",\"name\":\"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/novoeight.jpg\",\"datePublished\":\"2024-07-12T21:34:48+00:00\",\"dateModified\":\"2025-07-17T00:22:31+00:00\",\"description\":\"Learn how Novoeight is used to treat Hemophilia A. Topics include how the drug works, what it treats, side effects, dosages, and more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/novoeight.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/novoeight.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Hemophilia World Day. Doctor With Donor Blood Drop\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/hemophilia\\\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\",\"name\":\"Dr. Christine Leduc, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"caption\":\"Dr. Christine Leduc, PharmD\"},\"description\":\"Dr. Christine Leduc, PharmD, was born and raised in Irvine, CA. She attended college at Midwestern University, where she graduated cum laude. The most rewarding part of her job is suggesting lifestyle changes, educating patients on how their medication works, and precepting future pharmacists. Her areas of expertise are customer service and knowledge of specialty medication. Having worked in the service industry in the past, she has gained the customer service skills necessary to understand the needs of her patients. Dr. Leduc is currently precepting students from Marshall B. Ketchum University, University of Kansas, and Midwestern University. In her free time, she enjoys traveling, baking, and gardening. See Author Biography\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/christine-leduc\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Descripci\u00f3n general completa de Novoeight: Tratamiento de la hemofilia A con tecnolog\u00eda recombinante - Atenci\u00f3n especializada AmeriPharma\u00ae","description":"Aprenda c\u00f3mo se usa Novoeight para tratar la hemofilia A. Los temas incluyen c\u00f3mo funciona el medicamento, qu\u00e9 trata, efectos secundarios, dosis y m\u00e1s.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/","og_locale":"es_MX","og_type":"article","og_title":"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology - AmeriPharma\u00ae Specialty Care","og_description":"Learn how Novoeight is used to treat Hemophilia A. Topics include how the drug works, what it treats, side effects, dosages, and more.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-07-12T21:34:48+00:00","article_modified_time":"2025-07-17T00:22:31+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg","type":"image\/jpeg"}],"author":"Dr. Christine Leduc, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Christine Leduc, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/"},"author":{"name":"Dr. Christine Leduc, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/zh\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87"},"headline":"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology","datePublished":"2024-07-12T21:34:48+00:00","dateModified":"2025-07-17T00:22:31+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/"},"wordCount":960,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg","keywords":["Dr. Christine Leduc"],"articleSection":["Hemophilia"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/","url":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/","name":"Descripci\u00f3n general completa de Novoeight: Tratamiento de la hemofilia A con tecnolog\u00eda recombinante - Atenci\u00f3n especializada AmeriPharma\u00ae","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg","datePublished":"2024-07-12T21:34:48+00:00","dateModified":"2025-07-17T00:22:31+00:00","description":"Aprenda c\u00f3mo se usa Novoeight para tratar la hemofilia A. Los temas incluyen c\u00f3mo funciona el medicamento, qu\u00e9 trata, efectos secundarios, dosis y m\u00e1s.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg","width":1280,"height":853,"caption":"Hemophilia World Day. Doctor With Donor Blood Drop"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/hemophilia\/a-comprehensive-overview-of-novoeight-treating-hemophilia-a-with-recombinant-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"A Comprehensive Overview of Novoeight: Treating Hemophilia A with Recombinant Technology"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/zh\/#website","url":"https:\/\/ameripharmaspecialty.com\/zh\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/zh\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/zh\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/zh\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/zh\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/zh\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87","name":"Dra. Christine Leduc, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","caption":"Dr. Christine Leduc, PharmD"},"description":"La Dra. Christine Leduc, doctora en farmacia, naci\u00f3 y creci\u00f3 en Irvine, California. Curs\u00f3 estudios universitarios en la Universidad Midwestern, donde se gradu\u00f3 con honores. Lo m\u00e1s gratificante de su trabajo es sugerir cambios en el estilo de vida, educar a los pacientes sobre el funcionamiento de sus medicamentos y ser tutora de futuros farmac\u00e9uticos. Sus \u00e1reas de especializaci\u00f3n son la atenci\u00f3n al cliente y el conocimiento de medicamentos especializados. Tras haber trabajado en el sector servicios, ha adquirido las habilidades de atenci\u00f3n al cliente necesarias para comprender las necesidades de sus pacientes. Actualmente, la Dra. Leduc imparte clases a estudiantes de la Universidad Marshall B. Ketchum, la Universidad de Kansas y la Universidad Midwestern. En su tiempo libre, disfruta de viajar, la reposter\u00eda y la jardiner\u00eda. Ver biograf\u00eda de la autora.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"uagb_comment_info":0,"uagb_excerpt":"Novoeight (Turoctocog alfa) is an antihemophilic factor VIII produced via recombinant technology. This medication is generally prescribed to treat or prevent bleeding episodes in patients with hemophilia A.\u00a0Patients with hemophilia A lack clotting factor VIII (a blood clotting protein), and Novoeight replaces the missing clotting factor VIII, thereby helping the blood to clot.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/novoeight.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/hemophilia\/\" rel=\"category tag\">Hemophilia<\/a>","rttpg_excerpt":"Novoeight (Turoctocog alfa) is an antihemophilic factor VIII produced via recombinant technology. This medication is generally prescribed to treat or prevent bleeding episodes in patients with hemophilia A.\u00a0Patients with hemophilia A lack clotting factor VIII (a blood clotting protein), and Novoeight replaces the missing clotting factor VIII, thereby helping the blood to clot.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/26225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=26225"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/26225\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/26226"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=26225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=26225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=26225"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}